Cargando…

Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)

The objective of this retrospective study was to describe the responses to treatment with intravenous lipid emulsion (ILE) and the outcomes for a variety of severe intoxications. This case series includes 10 client-owned animals, 9 dogs and 1 cat, that underwent treatment with ILE for a variety of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Michael D, Young, Brian C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042488/
https://www.ncbi.nlm.nih.gov/pubmed/30050859
http://dx.doi.org/10.2147/VMRR.S129576
_version_ 1783339165614604288
author Becker, Michael D
Young, Brian C
author_facet Becker, Michael D
Young, Brian C
author_sort Becker, Michael D
collection PubMed
description The objective of this retrospective study was to describe the responses to treatment with intravenous lipid emulsion (ILE) and the outcomes for a variety of severe intoxications. This case series includes 10 client-owned animals, 9 dogs and 1 cat, that underwent treatment with ILE for a variety of severe intoxications over a 4-year period. History, physical examination findings, clinical signs, clinicopathological test results, treatment, response to treatment, and outcome were recorded. Eight of the 10 patients survived to discharge. The toxicities included in this case series were baclofen, ivermectin and spinosad plus milbemycin oxime, baclofen and tadalafil, carbamate, methamphetamine, dextroamphetamine sulfate, amlodipine, bromethalin, and organophosphate. The two patients who died were intoxicated with bromethalin and an organophosphate. Six of the 10 patients developed lipemia secondary to ILE administration, and there were no other known adverse effects. Overall, ILE was a safe therapeutic option. This case series provides clinical evidence of successful treatment with ILE as an antidote for previously unpublished toxicities (amlodipine, carbamate, methamphetamine, and dextroamphetamine sulfate), additional evidence of success in treating baclofen and ivermectin toxicosis, as well as unsuccessful treatment of bromethalin and organophosphate toxicities.
format Online
Article
Text
id pubmed-6042488
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60424882018-07-26 Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014) Becker, Michael D Young, Brian C Vet Med (Auckl) Case Series The objective of this retrospective study was to describe the responses to treatment with intravenous lipid emulsion (ILE) and the outcomes for a variety of severe intoxications. This case series includes 10 client-owned animals, 9 dogs and 1 cat, that underwent treatment with ILE for a variety of severe intoxications over a 4-year period. History, physical examination findings, clinical signs, clinicopathological test results, treatment, response to treatment, and outcome were recorded. Eight of the 10 patients survived to discharge. The toxicities included in this case series were baclofen, ivermectin and spinosad plus milbemycin oxime, baclofen and tadalafil, carbamate, methamphetamine, dextroamphetamine sulfate, amlodipine, bromethalin, and organophosphate. The two patients who died were intoxicated with bromethalin and an organophosphate. Six of the 10 patients developed lipemia secondary to ILE administration, and there were no other known adverse effects. Overall, ILE was a safe therapeutic option. This case series provides clinical evidence of successful treatment with ILE as an antidote for previously unpublished toxicities (amlodipine, carbamate, methamphetamine, and dextroamphetamine sulfate), additional evidence of success in treating baclofen and ivermectin toxicosis, as well as unsuccessful treatment of bromethalin and organophosphate toxicities. Dove Medical Press 2017-10-30 /pmc/articles/PMC6042488/ /pubmed/30050859 http://dx.doi.org/10.2147/VMRR.S129576 Text en © 2017 Becker and Young. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Series
Becker, Michael D
Young, Brian C
Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
title Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
title_full Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
title_fullStr Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
title_full_unstemmed Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
title_short Treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
title_sort treatment of severe lipophilic intoxications with intravenous lipid emulsion: a case series (2011–2014)
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042488/
https://www.ncbi.nlm.nih.gov/pubmed/30050859
http://dx.doi.org/10.2147/VMRR.S129576
work_keys_str_mv AT beckermichaeld treatmentofseverelipophilicintoxicationswithintravenouslipidemulsionacaseseries20112014
AT youngbrianc treatmentofseverelipophilicintoxicationswithintravenouslipidemulsionacaseseries20112014